80
Participants
Start Date
July 20, 2023
Primary Completion Date
August 31, 2027
Study Completion Date
November 15, 2028
GC012F (AZD0120)
GC012F (AZD0120) is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.
RECRUITING
Research Site, New York
RECRUITING
Research Site, Stony Brook
NOT_YET_RECRUITING
Research Site, Buffalo
RECRUITING
Research Site, Charlottesville
NOT_YET_RECRUITING
Research Site, Durham
NOT_YET_RECRUITING
Research Site, Charlotte
RECRUITING
Research Site, Atlanta
NOT_YET_RECRUITING
Research Site, Jacksonville
NOT_YET_RECRUITING
Research Site, Miami
RECRUITING
Research Site, Tampa
RECRUITING
Research Site, Birmingham
NOT_YET_RECRUITING
Research Site, Nashville
RECRUITING
Research Site, Nashville
NOT_YET_RECRUITING
Research Site, Nashville
NOT_YET_RECRUITING
Research Site, Ann Arbor
NOT_YET_RECRUITING
Research Site, Detroit
RECRUITING
Research Site, Iowa City
RECRUITING
Research Site, Milwaukee
NOT_YET_RECRUITING
Research Site, Minneapolis
RECRUITING
Research Site, Rochester
NOT_YET_RECRUITING
Research Site, Chicago
WITHDRAWN
Research Site, Omaha
RECRUITING
Research Site, Dallas
RECRUITING
Research Site, Houston
RECRUITING
Research Site, Austin
NOT_YET_RECRUITING
Research Site, Aurora
RECRUITING
Research Site, Denver
NOT_YET_RECRUITING
Research Site, Salt Lake City
RECRUITING
Research Site, Phoenix
NOT_YET_RECRUITING
Research Site, Los Angeles
RECRUITING
Research Site, La Jolla
NOT_YET_RECRUITING
Research Site, San Francisco
NOT_YET_RECRUITING
Research Site, Edmonds
NOT_YET_RECRUITING
Research Site, Seattle
NOT_YET_RECRUITING
Research Site, Boston
NOT_YET_RECRUITING
Research Site, Boston
WITHDRAWN
Research Site, Hackensack
Lead Sponsor
AstraZeneca
INDUSTRY